GSK Ventures Into The Device World Through Bioelectronic Investment
This article was originally published in The Pink Sheet Daily
The British pharma has financed a new venture fund to create a presence in an emerging technology and help jump-start the fledgling industry because it believes that the science has reached a transition point.
You may also be interested in...
Electroceuticals: Drug-Like Effects, Without The Drugs
Electroceuticals could replace the use of pharmaceuticals in many chronic diseases, offering effective treatments without, perhaps, side effects. Medtechs pioneering these next-gen neuromodulation devices are sparking investor interest.
GSK’s Focuses Bioelectronics Quest On Blocking Single-Organ Neural Signals
In the final part of its three-prong effort to advance the nascent field of bioelectronics, GSK will award a $1 million prize to researchers who are first able to solve the single-organ nerve interface challenge. Previously, the pharma launched its bioelectronics R&D unit and Action Potential Venture Capital to spur progress in this area.
Deals Of The Week: GSK’s Stealth Move To The Coasts
The British pharma opens new innovation centers in San Diego and Cambridge, Mass., to connect with those academic, business and venture investment communities. Also, Roche and Biogen Idec make moves in neurodegenerative disease, Retrophin makes two deals for different forms of the same drug, and GSK makes the latest alliance in the cancer immunology arena.